Crestor vs Repatha: Switching Between Them and What Women Need to Know

Why This Comparison Matters Specifically for Women

Heart disease is the leading cause of death in American women, yet women remain under-treated for high LDL at every stage of care. Understanding how rosuvastatin and evolocumab work, where they differ, and how to sequence them is not a niche clinical question. It is one of the most consequential decisions you and your clinician will make.

The comparison also plays out differently across your reproductive lifespan. A 32-year-old woman with familial hypercholesterolemia (FH) who is planning a pregnancy has an entirely different decision tree than a 58-year-old woman three years post-menopause with established atherosclerotic cardiovascular disease (ASCVD). Both drugs carry mandatory pregnancy warnings. Both drugs interact with hormonal shifts that reshape cardiovascular risk in women uniquely.

Sex-specific data on statins and PCSK9 inhibitors has been thinner than in men. The FOURIER trial enrolled about 24 percent women, and women-specific subgroup results were not powered to detect differences. Honest acknowledgment of that gap is part of how you should weigh any recommendation you receive.

How Cholesterol Changes Across a Woman's Life

During reproductive years, estrogen keeps LDL relatively lower and HDL relatively higher compared with age-matched men. Perimenopause changes that rapidly. LDL rises by an average of 10 to 14 mg/dL in the menopausal transition, independent of age, driven by falling estradiol. Triglycerides often rise simultaneously. Post-menopause, a woman's ASCVD risk trajectory steepens, and the window for starting lipid therapy to get maximum long-term benefit is earlier than many women are told.

PCOS is another major driver. Women with PCOS have higher rates of dyslipidemia, insulin resistance, and subclinical atherosclerosis even in their twenties and thirties. If you have PCOS, your lipid panel should be checked at diagnosis and annually, and your cardiometabolic risk is not the same as a woman without it.

How Rosuvastatin (Crestor) Works and What It Achieves

Rosuvastatin blocks HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. This upregulates LDL receptors on liver cells, which pull more LDL out of circulation. The drug is oral, taken once daily, and generic versions have been available since 2016 at a fraction of the branded Crestor price.

LDL Reduction and Cardiovascular Outcomes

The JUPITER trial enrolled 17,802 adults with LDL below 130 mg/dL but elevated high-sensitivity CRP (hsCRP) above 2.0 mg/L. Rosuvastatin 20 mg reduced the primary composite endpoint (MI, stroke, arterial revascularization, hospitalization for unstable angina, or CV death) by 44 percent versus placebo over a median follow-up of 1.9 years. The trial was stopped early because the benefit was so clear. LDL dropped from a median of 108 mg/dL to 55 mg/dL in the treatment group.

JUPITER included women, and the female subgroup showed a statistically significant reduction in the primary endpoint, which was not true of every statin trial before it. About 38 percent of JUPITER participants were women.

Dosing for Women

Rosuvastatin comes in 5, 10, 20, and 40 mg doses. Women of Asian descent metabolize rosuvastatin more slowly due to pharmacokinetic differences; the FDA label recommends starting at 5 mg in Asian patients rather than the standard 10 to 20 mg starting dose. Body composition differences between women and men also affect statin distribution; women carry proportionally more body fat and less lean mass, which may alter drug exposure at equivalent doses.

Common Side Effects in Women

Muscle-related symptoms (myalgia) occur at higher rates in women than men across the statin class. Women are also more likely to report statin-associated fatigue. A 2012 analysis found women had roughly twice the rate of statin discontinuation due to myalgia compared with men in observational data. New-onset diabetes is a recognized statin risk, and post-menopausal women have a modestly higher absolute risk of statin-related diabetes than men, though the cardiovascular benefit still outweighs this risk in most high-risk women.

Who Responds Best to Rosuvastatin

Rosuvastatin is typically first-line for:

• Primary prevention in women with elevated LDL or elevated hsCRP and at least moderate 10-year ASCVD risk
• Women with PCOS who have dyslipidemia and cannot conceive currently
• Women with familial hypercholesterolemia as the foundation of therapy
• Post-menopausal women newly identified with borderline or intermediate ASCVD risk

How Evolocumab (Repatha) Works and What It Achieves

Evolocumab is a monoclonal antibody that binds and inhibits PCSK9, a protein that degrades LDL receptors. Inhibiting PCSK9 keeps more LDL receptors on liver cell surfaces, which dramatically clears LDL from blood. It is injected subcutaneously either at 140 mg every two weeks or 420 mg once monthly using a prefilled autoinjector or SureClick device.

LDL Reduction and Cardiovascular Outcomes

The FOURIER trial enrolled 27,564 patients with established ASCVD already on optimized statin therapy. Adding evolocumab reduced LDL from a median of 92 mg/dL to 30 mg/dL, a reduction of approximately 59 percent. The primary endpoint (CV death, MI, stroke, unstable angina, or coronary revascularization) was reduced by 15 percent over a median of 2.2 years.

The secondary endpoint of hard MACE (CV death, MI, or stroke) was reduced by 20 percent. The absolute risk reduction was 1.5 percentage points, which translates to a number needed to treat of about 67 over 2.2 years, a clinically meaningful figure in a high-risk population.

The Women-Specific Evidence Gap in FOURIER

Women made up approximately 24 percent of FOURIER participants. The female subgroup results numerically trended in the same direction as the overall population, but the subgroup was not powered for definitive conclusions. The 2022 ACC/AHA cholesterol guidelines note that PCSK9 inhibitors reduce MACE in patients with established ASCVD, but acknowledge that most evidence derives from male-predominant trials. This is a documented evidence gap.

WomanRx uses a sex-stratified decision framework for escalating lipid therapy. For women considering a PCSK9 inhibitor, the decision involves four axes: (1) LDL target and current distance from it, (2) statin tolerability history, (3) reproductive plans within the next 12 months, and (4) insurance or access to manufacturer patient-assistance programs. No published guideline makes all four axes explicit for women. Applying them systematically changes who gets offered evolocumab and when.

Injection-Site Reactions and Women

Evolocumab's most common side effect is injection-site reactions, occurring in about 3 percent of patients in clinical trials. Nasopharyngitis and flu-like symptoms are also reported. Women in several post-marketing reports have noted that reactions are more frequent around the follicular phase, though no prospective study has confirmed hormonal variation in evolocumab tolerability. That is an open clinical question worth raising with your prescriber if you notice a cyclical pattern.

Switching Between Them: What "Switching" Actually Means Clinically

Most women asking about switching from Crestor to Repatha are really asking one of three different questions, and the answer differs by which question you mean.

Scenario 1: You Cannot Tolerate Rosuvastatin

If you have confirmed statin intolerance (persistent myalgia with two separate statins, documented by normal CK that resolves off statin and recurs on rechallenge), your clinician may consider evolocumab as a statin-free option. The 2022 ACC/AHA guideline supports PCSK9 inhibitor use in statin-intolerant patients with high or very-high ASCVD risk. In this scenario, you are substituting, not adding.

The catch is that most payers require documentation of statin intolerance with at least two separate statin trials, including a low-dose attempt with a different agent such as pitavastatin or pravastatin, before they will cover evolocumab.

Scenario 2: Your LDL Is Not at Goal on Rosuvastatin Alone

For women with very high ASCVD risk (established ASCVD, familial hypercholesterolemia, or LDL above 190 mg/dL), the ACC/AHA guideline recommends an LDL target below 70 mg/dL, and below 55 mg/dL for those with progressive ASCVD. If maximally tolerated rosuvastatin plus ezetimibe does not reach that target, evolocumab is added, not swapped. The statin stays; evolocumab layers on top.

Scenario 3: Cost or Access Concerns Drive the Question

Some women ask about switching because they cannot afford one or the other. Generic rosuvastatin costs approximately $10 to $30 per month at most pharmacies. Evolocumab without insurance or assistance typically runs $500 to $600 per month. Amgen's patient-assistance program (Repatha Now) may cover patients below certain income thresholds. If cost is driving the question, the realistic path for most women is to maximize generic rosuvastatin first.

Pregnancy, Lactation, and Contraception: Both Drugs Are Contraindicated or Unproven

This section is required reading if you are of reproductive age or planning a pregnancy.

Rosuvastatin in Pregnancy and Lactation

Rosuvastatin is FDA Pregnancy Category X. It is contraindicated in pregnancy. Statins inhibit cholesterol synthesis; cholesterol is essential for fetal neural and adrenal development. Case reports of fetal central nervous system and limb malformations have been associated with first-trimester statin exposure, though causality is not established definitively. The ACC/AHA and ACOG both recommend stopping statins before trying to conceive.

Stop rosuvastatin at least one month before trying to conceive. If you become pregnant while on rosuvastatin, stop immediately and contact your clinician.

Rosuvastatin is excreted in breast milk in small amounts in animal studies. Human lactation data is absent. Given the theoretical risk to the nursing infant and the option to defer lipid therapy, rosuvastatin is not recommended during breastfeeding.

Evolocumab in Pregnancy and Lactation

Evolocumab has no adequate, well-controlled studies in pregnant women. Animal reproductive studies with evolocumab have not shown direct fetal harm, but IgG antibodies cross the placenta, particularly in the second and third trimesters, and the fetal effect of PCSK9 inhibition is unknown. The Repatha prescribing information recommends using the drug during pregnancy only if the potential benefit justifies the potential risk.

For women with homozygous FH, where untreated LDL may exceed 400 mg/dL and pregnancy poses severe cardiovascular risk, the decision requires specialist consultation (typically a lipid specialist and maternal-fetal medicine together). Do not make that decision alone or with only a general practitioner.

Evolocumab is likely excreted in breast milk given that it is an IgG1 monoclonal antibody; IgG antibodies are present in human colostrum and milk. No human lactation data exists. The manufacturer advises considering the drug's importance to the mother when deciding about breastfeeding.

Contraception Requirement

If you are on rosuvastatin and sexually active with pregnancy possible, use reliable contraception. This is not optional. The same applies to women on evolocumab who have homozygous FH and whose treatment cannot be safely interrupted.

Life-Stage Breakdown: Who Should Get Which Drug When

Reproductive Years (Approx. Ages 18 to 44)

If you have FH or markedly elevated LDL and are not trying to conceive, rosuvastatin is appropriate with reliable contraception. Evolocumab is reserved for FH patients whose LDL is not controlled with statin plus ezetimibe, and for those who are truly statin-intolerant.

If you are trying to conceive or pregnant, neither drug should be used. A specialist may recommend LDL apheresis in severe FH during pregnancy.

Women with PCOS in this age group should be offered statin therapy if 10-year ASCVD risk reaches a threshold warranting treatment. PCOS itself is not an automatic indication for statin therapy, but it is a recognized risk-enhancer in the 2018 AHA/ACC prevention guidelines.

Perimenopause (Approx. Ages 45 to 55)

This is the most commonly missed window for initiating lipid therapy in women. LDL rises an average of 10 to 14 mg/dL, as documented in the Study of Women's Health Across the Nation (SWAN), and cardiovascular events begin to accelerate five to ten years post-menopause. Starting rosuvastatin in perimenopause, when the atherosclerotic process is still at an earlier stage, likely offers more benefit than starting a decade later.

Menopausal hormone therapy (MHT) does not replace statin therapy. Women on MHT who have elevated LDL should be on a statin as well. Oral estrogen raises triglycerides and may raise hsCRP, which could affect your ASCVD risk calculation.

Post-Menopause

Post-menopausal women with established ASCVD are the population most clearly supported by both JUPITER and FOURIER data. If you have had a heart attack, stroke, or coronary revascularization and your LDL is above 55 to 70 mg/dL on maximally tolerated statin therapy, evolocumab is a guideline-supported addition.

Post-menopausal women with osteoporosis should be aware that statin use has been associated with modest improvements in bone mineral density in observational data, though this is not an approved indication and the evidence is mixed.

Direct Comparison Table

| Feature | Rosuvastatin (Crestor) | Evolocumab (Repatha) | |---|---|---| | Drug class | Statin (oral) | PCSK9 inhibitor (injectable) | | LDL reduction | 45 to 55% | ~59% additional on statin | | Route | Oral, once daily | Subcutaneous injection q2w or q4w | | Typical cost (generic/brand) | $10 to 30/month generic | ~$500+/month without assistance | | Key trial | JUPITER (NEJM 2008) | FOURIER (NEJM 2017) | | CV event reduction | 44% vs placebo (JUPITER) | 15% primary endpoint (FOURIER) | | Pregnancy | Contraindicated (Category X) | Avoid; no adequate human data | | Lactation | Not recommended | Not recommended | | Women in key trial | ~38% (JUPITER) | ~24% (FOURIER) | | Main side effect in women | Myalgia, new-onset diabetes risk | Injection-site reactions | | Statin-free use | N/A | Yes, in confirmed statin intolerance |

Who This Is Right For and Who It Is Not

Rosuvastatin Is Likely Right for You If:

• Your LDL is above goal and you have not tried a statin
• You have intermediate or high ASCVD risk and want an oral, affordable, once-daily option
• You are in perimenopause with a newly rising LDL
• You have PCOS with dyslipidemia and are not planning pregnancy now
• You have FH and need the backbone of your lipid therapy

Rosuvastatin Is Not the Right Choice If:

• You are pregnant, breastfeeding, or actively trying to conceive
• You have confirmed intolerance to two separate statins
• Your LDL remains significantly above goal despite maximally tolerated rosuvastatin plus ezetimibe

Evolocumab Is Likely Right for You If:

• You have established ASCVD and LDL above 55 to 70 mg/dL on maximally tolerated statin therapy
• You have homozygous or severe heterozygous FH with inadequate LDL lowering on oral therapy
• You have documented statin intolerance (two statin trials) and high ASCVD risk
• You can access the drug through insurance or patient-assistance programs

Evolocumab Is Not the Right Choice If:

• You are pregnant or considering pregnancy in the near term without specialist guidance
• Your LDL is elevated but statin therapy has not yet been maximized
• Cost is prohibitive and patient-assistance programs do not apply to your income level

Monitoring After Switching or Adding

Whether you are transitioning from rosuvastatin to evolocumab (due to intolerance) or adding evolocumab to rosuvastatin, check a fasting lipid panel four to twelve weeks after the change. The ACC/AHA guideline recommends repeat lipid assessment at this interval to confirm response and guide further titration.

Monitor liver enzymes at baseline if not done recently; routine serial monitoring is no longer required by guidelines for most statin users, but baseline values are useful if symptoms develop. Creatine kinase (CK) should be checked if you develop myalgia; a normal CK with significant myalgia in the setting of statin use supports a clinical diagnosis of statin-associated muscle symptoms (SAMS) and warrants a drug holiday to assess causation.

For evolocumab, there are no required laboratory monitoring intervals beyond lipid panels. Injection-site inspection is standard self-monitoring. Store Repatha refrigerated at 36 to 46 degrees Fahrenheit; it can be kept at room temperature for up to 30 days.

If your LDL is not at goal four to eight weeks after starting or escalating therapy, return for follow-up. The target matters. A lipid panel result above 70 mg/dL in a woman with prior MI or stroke is an actionable finding, not something to recheck in six months.